<div id="readability-page-1"><p>In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$964.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Merle is a 3-star analyst with an average return of <span>3.8%</span> and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.</p> <p>In addition to Barclays, Madrigal Pharmaceuticals also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).</p></div>

MDGL

LABU

SBIO

<p>Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964.00. Merle, a 3-star analyst, has an average return of 3.8% and a 41.22% success rate. Additionally, H.C. Wainwright's Andrew Fein also issued a Buy rating for the company, while Bank of America Securities reiterated a Hold rating on the same day.</p>

Tip Ranks

Madrigal Pharma

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ALPS Medical Breakthrough

Barclays

Alnylam Pharma

Bridgebio Pharma

BioMarin Pharma

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays